In the specialized field of medicinal chemistry, the search for precision in cancer therapy is a constant pursuit. At the Medicinal Chemistry Group of the University of Antwerp, MSCA Postdoctoral Fellow Dr. Adrian Fabisiak is leading this charge through his project, PyroVector, which seeks to transform how we treat Acute Myeloid Leukemia (AML). We sat down with Adrian to discuss his journey from Warsaw to Antwerp and take a deep dive into his research.
